patient subgroup...
age >= 55 yr age >= 65 yr critical disease
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
convalescent plasma treatment - versus control - for COVID 19 hospitalized
pdf
xlsx
method
abbreviations
Outcome
Relative effect 95%CI
LoD
Trt. better when
I2
k (RCT/OBS)
Bayesian probability
Overall ROB
Publication bias
Degree of certainty
Endpoint importance
Published MA
efficacy endpoints 00 death D28 0.99 [0.93, 1.05]< 1 0% 28 studies (28/-) 65.7 % some concern critical moderate crucial - death or transfer to ICU 1.07 [0.73, 1.57]< 1 0% 1 study (1/-) 36.6 % NA not evaluable crucial - deaths 0.73 [0.53, 1.02]< 1 97% 48 studies (44/4) 96.5 % moderate critical moderate crucial 1 deaths (time to event analysis only) 0.83 [0.38, 1.84]< 1 96% 8 studies (8/-) 67.5 % some concern serious moderate crucial - clinical deterioration 0.89 [0.75, 1.06]< 1 0% 6 studies (6/-) 90.6 % some concern not evaluable moderate important - clinical improvement 1.09 [0.87, 1.38]> 1 39% 8 studies (8/-) 77.9 % some concern not evaluable moderate important - clinical improvement (14-day) 2.27 [0.90, 5.72]> 1 0% 1 study (1/-) 95.9 % NA not evaluable important - clinical improvement (28-day) 1.33 [0.83, 2.14]> 1 53% 5 studies (5/-) 88.1 % some concern not evaluable moderate important - clinical improvement (7-day) 0.98 [0.27, 3.58]> 1 0% 1 study (1/-) 48.8 % NA not evaluable important - clinical improvement (time to event analysis only) 1.08 [0.90, 1.29]> 1 0% 5 studies (5/-) 80.5 % low not evaluable high important - death or ventilation 0.98 [0.94, 1.03]< 1 0% 5 studies (5/-) 79.2 % some concern not evaluable moderate important - hospital discharge 1.00 [0.94, 1.07]> 1 0% 3 studies (3/-) 52.3 % some concern not evaluable moderate important - mechanical ventilation 0.89 [0.74, 1.07]< 1 11% 8 studies (8/-) 89.5 % some concern not evaluable moderate important 1 mechanical ventilation (time to event analysis only) 0.97 [0.62, 1.52]< 1 0% 2 studies (2/-) 55.5 % some concern not evaluable moderate important - viral clearance 1.10 [0.19, 6.30]> 1 0% 2 studies (2/-) 54.1 % some concern not evaluable moderate important - viral clearance by day 14 0.96 [0.77, 1.20]> 1 0% 2 studies (2/-) 35.7 % some concern not evaluable moderate important - viral clearance by day 7 1.05 [0.81, 1.36]> 1 41% 3 studies (3/-) 64.8 % high not evaluable low important - ICU admission 0.67 [0.32, 1.41]< 1 1% 2 studies (2/-) 85.6 % some concern not evaluable moderate non important - off oxygenation 0.26 [0.02, 2.88]> 1 0% 1 study (1/-) 13.8 % NA not evaluable non important - safety endpoints 00 serious adverse events 1.19 [0.94, 1.50]< 1 45% 6 studies (6/-) 7.8 % some concern not evaluable moderate important - adverse events 1.08 [0.86, 1.37]< 1 0% 2 studies (2/-) 24.8 % some concern not evaluable moderate non important -
LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias;
suggested: nominally statistically significant but without a strict control of overall risk of type 1 error;
inconclusive: not nominally statistically significant;
safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies;
published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE.
Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.